Seegene and Accuramed are pleased to announce the Nature Awards MDx Impact Grants to develop new and innovating syndromic PCR assays as a second phase of last years Open Innovation Program.
The MDx Impact Grants aim to unlock the potential of PCR to democratise access to accurate diagnostic tests that improve patient outcomes.
Research groups are invited to work with Seegene to develop tests that address unmet clinical needs. The programme provides researchers with access to Seegene’s syndromic PCR technology and development grants to perform clinical studies.
Research groups are permitted to submit up to three project applications per funding cycle. We welcome applications from eligible research groups from around the world.
2024 Scope: human infectious diseases
This year, the MDx Impact Grants focus on diagnostic tests for human infectious diseases. Applicants are required to identify suitable pathogen targets, including, if clinically relevant, any variants or subtypes, and perform clinical studies for syndromic PCR diagnostic tests of human infectious diseases. Applications need to be registered by December 2nd 2024.
Before you apply
Seegene invite applications from eligible research groups all around the world. Research groups are required to have access to BSL-2 (Biosafety level 2) facilities, experience in PCR, access to relevant clinical specimens and experience in performing clinical studies for medical device validation. At the time of submission, all applicants are required to state that they have reviewed and agree to the Terms and Conditions of the programme.
Within the Benelux you can reach out to Accuramed or apply in the nature link below.
Smaakt naar meer?
We stellen onze expertise in analyse en advies graag ter beschikking om de beste oplossing voor u, uw organisatie en patiënt samen te stellen. Neem contact en ervaar het verschil.